|
Vancouver, Canada – July 3, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) is pleased to announce that clinical development of Sirona’s SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events. Diabetes TFC-039 Wanbang / Fosun (China) Ready for licensing in ROW (Rest of World) |
|
| aus der Diskussion: | Sirona Biochem |
| Autor (Datum des Eintrages): | Soxbomb (12.10.19 18:23:04) |
| Beitrag: | 17,050 von 31,047 (ID:61681101) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |